See more : Clear Blue Technologies International Inc. (CBLU.V) Income Statement Analysis – Financial Results
Complete financial analysis of Electromed, Inc. (ELMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Electromed, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Tuscan Holdings Corp. (THCBW) Income Statement Analysis – Financial Results
- Charbone Hydrogen Corporation (CH.V) Income Statement Analysis – Financial Results
- Canare Electric Co., Ltd. (5819.T) Income Statement Analysis – Financial Results
- China Traditional Chinese Medicine Holdings Co. Limited (CHIZF) Income Statement Analysis – Financial Results
- Shanxi Changcheng Microlight Equipment Co. Ltd. (8286.HK) Income Statement Analysis – Financial Results
Electromed, Inc. (ELMD)
About Electromed, Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.72M | 48.07M | 41.66M | 35.76M | 32.47M | 31.30M | 28.70M | 25.86M | 22.99M | 19.41M | 15.49M | 15.10M | 19.52M | 19.00M | 14.30M | 13.00M | 8.75M |
| Cost of Revenue | 12.99M | 11.55M | 10.22M | 8.45M | 7.27M | 7.45M | 5.84M | 5.29M | 5.12M | 5.81M | 4.85M | 4.66M | 5.38M | 5.23M | 3.71M | 3.34M | 2.15M |
| Gross Profit | 41.73M | 36.52M | 31.44M | 27.31M | 25.20M | 23.85M | 22.86M | 20.57M | 17.88M | 13.60M | 10.63M | 10.45M | 14.15M | 13.78M | 10.60M | 9.66M | 6.61M |
| Gross Profit Ratio | 76.26% | 75.98% | 75.47% | 76.36% | 77.61% | 76.19% | 79.64% | 79.53% | 77.75% | 70.07% | 68.66% | 69.18% | 72.45% | 72.50% | 74.08% | 74.30% | 75.47% |
| Research & Development | 656.00K | 916.00K | 1.36M | 1.72M | 1.05M | 583.31K | 251.44K | 596.88K | 380.39K | 315.65K | 466.06K | 603.38K | 920.77K | 1.03M | 600.99K | 357.87K | 271.24K |
| General & Administrative | 33.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.60M | 16.40M | 14.39M | 11.97M | 10.91M | 11.67M | 12.62M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 499.00K | 589.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.49M | 31.60M | 27.11M | 22.44M | 19.94M | 20.45M | 19.60M | 16.40M | 14.39M | 11.97M | 10.91M | 11.67M | 12.62M | 10.87M | 8.20M | 6.85M | 6.00M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -12.00K | -913.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.87M | 8.20M | 6.85M | 6.00M |
| Operating Expenses | 35.15M | 32.51M | 28.47M | 24.17M | 20.08M | 21.03M | 19.85M | 17.00M | 14.77M | 12.29M | 11.37M | 12.28M | 13.54M | 11.91M | 8.80M | 7.20M | 6.27M |
| Cost & Expenses | 48.14M | 44.06M | 38.69M | 32.62M | 27.35M | 28.48M | 25.69M | 22.29M | 19.88M | 18.10M | 16.23M | 16.93M | 18.92M | 17.13M | 12.51M | 10.54M | 8.42M |
| Interest Income | 455.00K | 78.00K | 25.00K | 39.00K | 120.75K | 90.71K | 0.00 | 17.04K | 0.00 | 284.00 | 12.39K | 16.72K | 8.40K | 10.92K | 6.42K | 8.75K | 24.82K |
| Interest Expense | 0.00 | 0.00 | 25.00K | 0.00 | 0.00 | 0.00 | 19.87M | 66.91K | 66.81K | 85.99K | 91.40K | 133.56K | 177.13K | 191.33K | 269.85K | 279.19K | 501.69K |
| Depreciation & Amortization | 841.00K | 613.00K | 628.00K | 610.00K | 738.23K | 925.23K | 790.03K | 755.13K | 738.70K | 736.22K | 695.55K | 589.86K | 532.63K | 449.47K | 351.75K | 318.95K | 268.40K |
| EBITDA | 7.42M | 4.62M | 3.60M | 3.75M | 5.86M | 3.74M | 3.80M | 4.32M | 3.85M | 2.05M | -32.65K | -1.24M | 1.15M | 2.33M | 2.15M | 2.77M | 627.43K |
| EBITDA Ratio | 13.56% | 9.61% | 8.64% | 10.49% | 18.04% | 11.96% | 13.24% | 16.72% | 16.74% | 10.54% | -0.21% | -8.08% | 5.88% | 12.21% | 15.06% | 21.41% | 7.17% |
| Operating Income | 6.58M | 4.01M | 2.97M | 3.14M | 5.12M | 2.82M | 3.01M | 3.57M | 3.11M | 1.31M | -740.59K | -1.83M | 606.34K | 1.87M | 1.80M | 2.46M | 334.22K |
| Operating Income Ratio | 12.03% | 8.34% | 7.13% | 8.78% | 15.76% | 9.00% | 10.48% | 13.80% | 13.52% | 6.75% | -4.78% | -12.10% | 3.11% | 9.84% | 12.56% | 18.89% | 3.82% |
| Total Other Income/Expenses | 455.00K | 78.00K | 25.00K | 27.00K | 120.75K | 101.82K | -276.35K | -49.87K | -66.81K | -85.71K | -79.00K | -116.88K | -168.73K | -191.33K | -263.43K | -270.45K | -476.87K |
| Income Before Tax | 7.04M | 4.09M | 3.00M | 3.17M | 5.24M | 2.91M | 3.03M | 3.52M | 3.04M | 1.22M | -819.59K | -1.94M | 437.61K | 1.68M | 1.53M | 2.19M | -142.65K |
| Income Before Tax Ratio | 12.86% | 8.50% | 7.19% | 8.86% | 16.14% | 9.29% | 10.55% | 13.61% | 13.23% | 6.31% | -5.29% | -12.87% | 2.24% | 8.83% | 10.71% | 16.81% | -1.63% |
| Income Tax Expense | 1.89M | 920.00K | 692.00K | 805.00K | 1.08M | 940.00K | 1.13M | 1.29M | 830.00K | 132.00K | 469.00K | -615.00K | 251.00K | 623.00K | 599.00K | 830.00K | -427.00K |
| Net Income | 5.15M | 3.17M | 2.31M | 2.36M | 4.16M | 1.97M | 1.90M | 2.23M | 2.21M | 1.09M | -1.29M | -1.33M | 186.61K | 1.06M | 916.34K | 1.33M | 267.85K |
| Net Income Ratio | 9.41% | 6.59% | 5.53% | 6.61% | 12.81% | 6.29% | 6.63% | 8.62% | 9.62% | 5.63% | -8.32% | -8.80% | 0.96% | 5.55% | 6.41% | 10.25% | 3.06% |
| EPS | 0.60 | 0.37 | 0.27 | 0.28 | 0.50 | 0.24 | 0.23 | 0.27 | 0.27 | 0.13 | -0.16 | -0.16 | 0.02 | 0.14 | 0.15 | 0.22 | 0.05 |
| EPS Diluted | 0.58 | 0.36 | 0.26 | 0.27 | 0.47 | 0.23 | 0.22 | 0.26 | 0.27 | 0.13 | -0.16 | -0.16 | 0.02 | 0.13 | 0.15 | 0.22 | 0.04 |
| Weighted Avg Shares Out | 8.56M | 8.46M | 8.47M | 8.57M | 8.40M | 8.31M | 8.21M | 8.17M | 8.14M | 8.12M | 8.05M | 8.11M | 8.11M | 7.82M | 6.08M | 5.99M | 5.44M |
| Weighted Avg Shares Out (Dil) | 8.86M | 8.70M | 8.77M | 8.91M | 8.83M | 8.63M | 8.62M | 8.46M | 8.25M | 8.15M | 8.11M | 8.11M | 8.11M | 7.84M | 6.11M | 6.02M | 6.45M |
4 Stocks Trading Near 52-Week High That Can Scale Higher
Why Soaring Health Industry Stock DexCom is a Strong Buy Right Now
5 Top Low-Beta Stocks Surged in March Defying Coronavirus
Former England international Kevin Davies signs up to help NHS in coronavirus battle
Top Ranked Momentum Stocks to Buy for February 21st
Source: https://incomestatements.info
Category: Stock Reports